文献速递胸部肿瘤

纳武利尤单抗治疗的非小细胞肺癌患者中EGFR-TKI相关间质性肺炎

EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2018-01-01

95%CI 4.51-5.10)发生间质性肺炎。5777例接受EGFR-TKI治疗者中265例发生IP(4.59%;95%CI 4.06-5.16),70例同时接受EGFR-TKI和纳武利尤单抗者中18例发生IP(25.7%;95%CI 16.0-37.6)。EGFR-TKI与纳武利尤单抗交互作用的调整OR为4.31(95%CI 2.37-7.86;P<.001)。

要点

  • EGFR-TKI联合纳武利尤单抗者IP发生比例高于单药治疗。
  • 两药交互作用调整OR为4.31(95%CI 2.37-7.86;P<.001)。
  • 联合或序贯使用时应警惕IP风险并密切监测。

核心结论

  • 纳武利尤单抗联合EGFR-TKI相比任一单药治疗,IP报告比例更高。
  • 结果受研究局限性影响需进一步确认,但联合或序贯使用时应谨慎考虑IP风险增加并密切监测。

研究设计与样本

  • 比较接受与未接受纳武利尤单抗治疗患者中EGFR-TKI相关IP的发生率。

主要发现

  • 5777例接受EGFR-TKI治疗患者中265例发生IP(4.59%;95%CI 4.06-5.16)。
  • 70例同时接受EGFR-TKI和纳武利尤单抗治疗患者中18例发生IP(25.7%;95%CI 16.0-37.6)。
  • EGFR-TKI与纳武利尤单抗交互作用的调整OR为4.31(95%CI 2.37-7.86;P<.001)。
  • 按是否接受纳武利尤单抗分层,EGFR-TKI相关IP的OR分别为5.09(95%CI 2.87-9.03)和1.22(95%CI 1.00-1.47)。

临床怎么用

  • EGFR-TKI与纳武利尤单抗联合或序贯使用时,应谨慎评估并密切监测间质性肺炎。

局限性

  • 研究为数据库不良事件报告分析,存在其固有局限性,结果需进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Nivolumab and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are now the standard-of-care therapies in non-small cell lung cancer (NSCLC). Although EGFR-TKIs are well understood and have well-defined safety profiles, our experience with immune checkpoint inhibitors is still growing, particularly regarding the use of combinations of different classes of antitumor agents, including both the concomitant and sequential use of such agents. OBJECTIVE: To determine whether nivolumab increases EGFR-TKI-associated interstitial pneumonitis (IP). DESIGN, SETTING, AND PARTICIPANTS: A database study of 20 516 participants with NSCLC in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database, performed between April 2015 and March 2017. MAIN OUTCOMES AND MEASURES: We compared the incidence of EGFR-TKI-associated IP in patients receiving and not receiving nivolumab treatment. RESULTS: The mean (SD) age of participants treated with EGFR-TKI, with and without nivolumab, was 64.4 (15.5) and 68.9 (11.8) years, respectively, and the proportion of men was 40.0% and 53.8%, respectively. Of the 20 516 participants with NSCLC, 985 cases (4.80%; 95% CI, 4.51-5.10) developed IP. Of 5777 patients treated with EGFR-TKI, 265 developed IP (4.59%; 95% CI, 4.06-5.16). Of 70 patients treated with both EGFR-TKI and nivolumab, 18 developed IP (25.7%; 95% CI, 16.0-37.6). The adjusted odds ratio for an interaction between EGFR-TKI and nivolumab was 4.31 (95% CI, 2.37-7.86; P < .001), suggesting the existence of an interaction. When we further stratified the patients by treatment with and without nivolumab, the odds ratio of EGFR-TKI-associated IP in cases with and without nivolumab treatment was 5.09 (95% CI, 2.87-9.03) and 1.22 (95% CI, 1.00-1.47), respectively. CONCLUSIONS AND RELEVANCE: We found a higher proportion of reports of IP for nivolumab in combination with EGFR-TKI vs treatment with either drug alone. Owing to the limitations of this study, the results warrant further confirmation. However, careful consideration should be given to the possibility of an increased risk of IP when EGFR-TKI is administered in combination with nivolumab, including concomitant and sequential use, and careful monitoring for IP is recommended.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. JAMA Oncol. 2018. PMID: 29327061. doi:10.1001/jamaoncol.2017.4526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。